Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
about
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyMERTK as a novel therapeutic target in head and neck cancer.Temporal characterization of lymphatic metastasis in an orthotopic mouse model of oral cancer.Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks TumorigenesisModulation of RTK by sEcad: a putative mechanism for oncogenicity in oropharyngeal SCCs.
P2860
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@ast
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@en
type
label
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@ast
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@en
prefLabel
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@ast
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@en
P2860
P356
P1476
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.
@en
P2093
Lisa A Elferink
Vicente A Resto
P2860
P304
P356
10.1155/2011/982879
P577
2011-06-07T00:00:00Z